Last update: Aug. 11, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Dapagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014).
Administered orally once a day.
Since the last update, we have not found published data on its excretion in breast milk.
Its pharmacokinetic characteristics (moderately elevated molecular weight, high plasma protein binding and large volume of distribution: EMA 2017), make it very unlikely its excretion into breast milk in significant amounts.
It has a low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (EMA 2017, Plosker 2014).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise and breastfeeding improve blood glucose levels.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM